None
Quote | H/Cell Energy Corp (OTCMKTS:HCCC)
Last: | $0.15 |
---|---|
Change Percent: | -40.0% |
Open: | $0.25 |
Close: | $0.15 |
High: | $0.25 |
Low: | $0.15 |
Volume: | 6,667 |
Last Trade Date Time: | 10/05/2020 04:44:07 am |
News | H/Cell Energy Corp (OTCMKTS:HCCC)
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...
Message Board Posts | H/Cell Energy Corp (OTCMKTS:HCCC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
H/Cell Energy Corp Company Name:
HCCC Stock Symbol:
OTCMKTS Market:
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, C...